VNDA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Vanda Pharmaceuticals Inc (VNDA) is not a strong buy at this time for a beginner investor with a long-term strategy. While the stock has potential upside based on analysts' price targets and recent FDA approvals, the negative financial performance, weak technical indicators, and ongoing investigations create significant risks. A hold is recommended until further clarity on financial stability and regulatory issues emerges.
The MACD is negative and expanding, indicating bearish momentum. RSI is neutral at 20.964, with no clear signal. Moving averages are converging, suggesting indecision in price trends. Key support is at 6.32, and resistance is at 8.074. The stock is trading near support levels, but there is no strong technical signal for a buy.
FDA approval of Nereus for motion sickness prevention, which could unlock $100M-$300M in revenue.
Analysts have reiterated buy ratings with price targets significantly higher than the current price, indicating potential long-term upside.
Recent Q4 financial results missed estimates, with a significant net income loss of -$141M and weak revenue guidance for
Ongoing investigation for potential securities fraud following an FDA rejection.
Plans to raise $200M through securities offerings, which could dilute shareholder value.
In Q4 2025, revenue increased by 7.58% YoY to $57.2M, but net income showed a massive loss of -$141.2M, up 2774.33% YoY. EPS also declined significantly to -$2.39, up 2887.50% YoY. Gross margin dropped slightly to 90.24%. Overall, financial performance is weak, with significant losses overshadowing revenue growth.
Analysts are generally positive on VNDA, with multiple buy ratings and price targets ranging from $7.50 to $22. Recent FDA approval of Nereus has been highlighted as a key growth driver, but concerns remain over financial stability and regulatory challenges.
